FOSAMPRENAVIR CALCIUM (LEXIVA, TELZIR)

Course overview

Fosamprenavir (FPV) is a protease inhibitor (PI) that is FDA-approved to treat HIV-1 infections in adults and children ≥ 2 years, in combination with other antiretrovirals as part of highly-active antiretroviral therapy (HAART). It must be used with caution in patients with hemophilia A/B, underlying hepatitis B/C, hepatic impairment, indolent or residual opportunistic infections, pre-existing transaminase elevations, or history of sulfonamide allergy. This continuing education module is designed to give the reader/learner an increased understanding of FPV. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.